1 completed, 1 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow Foster®: new trials by email Literature Review of Foster® trials Research Report on Foster®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation), Foster® 200/6 pMDI (BDP/FF-200/6 µg) - Asthma | Phase 4 | Recruiting | Chiesi Farmaceutici S.p.A. | 644 | 2026-06-28 | 2026-07-31 |
| CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD CHF5993, CHF1535, Matched placebo - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Chiesi Farmaceutici S.p.A. | 106 | 2021-10-28 | 2023-03-24 |
Asthma (1) · Pulmonary Disease, Chronic Obstructive (1)
Chiesi Farmaceutici S.p.A. (2)
Bulgaria (1) · Germany (1)
Henrik Watz, MD (1)
2025 (1)